Novel Approach of Human Epidermal Growth Factor Receptor 2 Detection in Noninvasive and Invasive Transitional Cell Carcinoma of the Bladder

No AccessJournal of UrologyAdult urology1 Mar 2006Novel Approach of Human Epidermal Growth Factor Receptor 2 Detection in Noninvasive and Invasive Transitional Cell Carcinoma of the Bladderis accompanied byGene Expression Profiling of ERBB Receptors and Ligands in Human Transitional Cell Carcinoma of the Bladder C. Hauser-Kronberger, K. Peham, J. Grall, W. Rausch, G. Hutarew, and O. Dietze C. Hauser-KronbergerC. Hauser-Kronberger Department of Pathology, General Hospital and Paracelsus University Salzburg , K. PehamK. Peham Department of Pathology, General Hospital and Paracelsus University Salzburg Department of Molecular Biology, University of Salzburg, Salzburg , J. GrallJ. Grall Department of Pathology, General Hospital and Paracelsus University Salzburg , W. RauschW. Rausch Department of Pathology, Voecklabruck Hospital, Voecklabruck, Austria , G. HutarewG. Hutarew Department of Pathology, General Hospital and Paracelsus University Salzburg , and O. DietzeO. Dietze Department of Pathology, General Hospital and Paracelsus University Salzburg View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)00411-8AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: In recent years over expression of HER2 has been identified in malignant tumors of organs other than breast. Studies of bladder carcinoma that analyzed HER2 protein expression and gene amplification with a variety of nonstandardized methods have shown heterogeneous results. The results reported vary from 2% to 74% of protein over expression, to 4% to 59% of gene amplification of HER2, possibly due to differences in study design, material selection or laboratory methodology. Materials and Methods: In the present study archival tissue from 87 patients with noninvasive papillary (25) and invasive (62) TCC was analyzed for amplification of the HER2 gene and over expression of its encoded protein. HER2 protein expression was detected by immunohistochemistry using the HercepTest®. Routinely processed paraffin embedded tissue was investigated for HER2 gene amplification using CISH and FISH. Results: Of the invasive 37 (58%) and of the noninvasive 19 (76%) transitional cell carcinomas investigated showed over expression of the HER2 protein (3+ and 2+) using a standardized immunohistochemical method. HER2 gene amplification assays performed on positive cases evaluated by immunohistochemistry were obtained in 81% and 43% of 3+ and 2+ HER2 protein over expressing invasive, respectively, and in 21% of noninvasive papillary bladder tumors. HER2 gene amplification detection results using CISH and FISH showed a concordance of 100%. The occurrence of aneusomy of chromosome 17 in association with HER2 gene amplification was investigated. Conclusions: Validation of the HER2 oncogene in bladder cancer may allow for the potential use of Herceptin® antibody therapy. Therefore, the appropriate treatment approach has to be based on reliable and standardized analysis. Our results indicate that CISH could provide an accurate and practical alternative to FISH for the clinical diagnosis of HER2 oncogene amplification in bladder cancer. References 1 : Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. Mol Carcinog1990; 3: 254. Google Scholar 2 : Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res1993; 53: 2199. Google Scholar 3 : Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?. Cancer2002; 95: 1009. Google Scholar 4 : HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder prognostic implications. Int J Cancer2002; 102: 514. Google Scholar 5 : HER-2—a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol2002; 41: 282. Google Scholar 6 : HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?. Eur J Cancer2004; 40: 56. Google Scholar 7 : Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/ neu (c-erbb-2) status in urothelial carcinoma. Virchows Arch2004; 444: 415. Google Scholar 8 : The clinical evaluation of HER-2 status: which test to use?. J Pathol2003; 199: 411. Google Scholar 9 : Current perspectives on HER2 testing a review of national testing guidelines. Mod Pathol2003; 16: 173. Google Scholar 10 : Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol2000; 157: 1467. Google Scholar 11 : Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest2002; 82: 1007. Google Scholar 12 : Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer. J Mol Histol2004; 35: 647. Google Scholar 13 : Concomitant oncoprotein detection with fluorescence in situ hybridization (CODFISH) a fluorescence-based assay enabling simultaneous visualization of gene amplification and encoded protein expression. J Mol Diagn2000; 2: 78. Google Scholar 14 : Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol2002; 15: 657. Google Scholar 15 : Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer2003; 88: 1587. Google Scholar 16 : Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res2004; 10: 4793. Google Scholar 17 : Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol2003; 199: 418. Google Scholar 18 : HER-2/neu gene amplification characterized by fluorescence in situ hybridization poor prognosis in node-negative breast carcinomas. J Clin Oncol1997; 15: 2894. Google Scholar 19 : Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Clin Pathol2003; 119: 381. Google Scholar © 2006 by American Urological AssociationFiguresReferencesRelatedDetailsCited byGomella L (2018) Targeting the Genetic Basis of Transitional Cell CarcinomaJournal of Urology, VOL. 175, NO. 6, (1986-1986), Online publication date: 1-Jun-2006.Related articlesJournal of Urology9 Nov 2018Gene Expression Profiling of ERBB Receptors and Ligands in Human Transitional Cell Carcinoma of the Bladder Volume 175Issue 3March 2006Page: 875-880 Advertisement Copyright & Permissions© 2006 by American Urological AssociationKeywordsepidermal growth factor receptor related proteinhumanbladder neoplasmsimmunohistochemistryin situ hybridizationMetricsAuthor Information C. Hauser-Kronberger Department of Pathology, General Hospital and Paracelsus University Salzburg More articles by this author K. Peham Department of Pathology, General Hospital and Paracelsus University Salzburg Department of Molecular Biology, University of Salzburg, Salzburg Recipient of a scholarship from the Medizinische Forschungsgesellschaft Salzburg, General Hospital and Paracelsus University Salzburg, Austria. More articles by this author J. Grall Department of Pathology, General Hospital and Paracelsus University Salzburg More articles by this author W. Rausch Department of Pathology, Voecklabruck Hospital, Voecklabruck, Austria More articles by this author G. Hutarew Department of Pathology, General Hospital and Paracelsus University Salzburg More articles by this author O. Dietze Department of Pathology, General Hospital and Paracelsus University Salzburg More articles by this author Expand All Advertisement PDF downloadLoading ...